Alpha Crest Capital Management LLC Dexcom Inc Transaction History

Alpha Crest Capital Management LLC

$0
Q4 2022

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $338,230 - $417,217	-4,430 Reduced 23.84%	14,154 $1.14 Million
Q2 2022 Aug 11, 2022	BUY	$67.99 - $132.89 $1.18 Million - $2.31 Million	17,355 Added 1412.12%	18,584 $1.39 Million
Q1 2022 May 12, 2022	SELL	$94.08 - $130.2 $787,167 - $1.09 Million	-8,367 Reduced 87.19%	1,229 $629,000
Q4 2021 Feb 09, 2022	BUY	$129.87 - $162.82 $1.13 Million - $1.41 Million	8,674 Added 940.78%	9,596 $5.15 Million
Q3 2021 Nov 10, 2021	SELL	$106.71 - $143.18 $101,374 - $136,021	-950 Reduced 50.75%	922 $504,000
Q2 2021 Aug 12, 2021	SELL	$80.99 - $107.93 $48,755 - $64,973	-602 Reduced 24.33%	1,872 $799,000
Q1 2021 May 13, 2021	SELL	$84.79 - $104.74 $57,572 - $71,118	-679 Reduced 21.54%	2,474 $889,000
Q4 2020 Feb 12, 2021	SELL	$78.0 - $104.5 $39,156 - $52,459	-502 Reduced 13.73%	3,153 $1.17 Million
Q3 2020 Nov 12, 2020	BUY	$95.51 - $112.95 $28,270 - $33,433	296 Added 8.81%	3,655 $1.51 Million
Q2 2020 Aug 12, 2020	SELL	$62.68 - $105.34 $31,026 - $52,143	-495 Reduced 12.84%	3,359 $1.36 Million
Q1 2020 May 13, 2020	SELL	$47.79 - $75.63 $117,133 - $185,369	-2,451 Reduced 38.87%	3,854 $1.04 Million
Q4 2019 Feb 12, 2020	SELL	$36.62 - $57.29 $119,088 - $186,307	-3,252 Reduced 34.03%	6,305 $1.38 Million
Q3 2019 Nov 12, 2019	BUY	$35.53 - $43.8 $284,808 - $351,100	8,016 Added 520.18%	9,557 $1.43 Million
Q2 2019 Aug 12, 2019	SELL	$27.84 - $38.92 $330,126 - $461,513	-11,858 Reduced 88.5%	1,541 $231,000
Q1 2019 May 10, 2019	BUY	$28.07 - $38.18 $376,109 - $511,573	13,399 New	13,399 $1.6 Million

Others Institutions Holding DXCM

# of Institutions

1,084

Shares Held

352M

Call Options Held

8.45M

Put Options Held

5.75M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $33.2B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Crest Capital Management LLC with notifications on news.

Account